Celcuity
Hamel
About Celcuity
Celcuity is a clinical-stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity's 3rd generation diagnostic platform, CELsignia, analyzes living tumor cells to untangle the complexity of the cellular activity driving a patient's cancer. This allows Celcuity to discover new cancer sub-types molecular diagnostics cannot detect. Celcuity is driven to improve outcomes for patients and to transform how pharmaceutical companies define the patient populations for their targeted therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $1.1B
- Funding stage: IPO
- Last round: Post-IPO Debt (Sep 2025)
- Ticker: nasdaq:CELC
- Website: celcuity.com
- Phone: 763-473-0341
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/celcuity-60275 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.